PL BioScience Taps Oliver Dick as Chief Technology Officer

PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, has appointed Oliver Dick, PhD, as Chief Technology Officer, a strategic position as the company scales up to meet growing global demand for its animal-free cell culture solutions.

“Oliver has an extensive track record in operational excellence and brings a strategic vision as well as hands-on leadership in life sciences and biopharma manufacturing to our team. With global demand for animal-free cell culture supplements increasing, we are advancing our international growth strategy and are delighted to have him as we enter into this exciting phase,” said Dr. Hatim Hemeda, CEO of PL BioScience.

Experience

Dick is an experienced operations executive with over 30 years of experience in project and line management across supply chain management (SCM), production, quality control (QC), quality assurance (QA), logistics, engineering and technology transfer. His expertise lies in developing and leading operational strategies along the entire supply chain within life science, diagnostic, and biopharmaceutical organizations.

Prior to joining PL BioScience, Dick held senior leadership roles including Chief Operating Officer and Vice President of Operations at both global biotech companies such as Resolve BioSciences, Rentschler, and Miltenyi Biotec, as well as international corporations including Fresenius and Qiagen. Throughout his career, he has consistently driven cross-functional initiatives aimed at process optimization, cost reduction, and digital transformation across the supply chain.

He holds an engineering degree and a PhD in biochemical engineering from the Technical University of Dortmund.

“I am very excited to join PL BioScience as CTO at a time of such dynamic growth and opportunity,” said Dick. “The company has built a strong reputation for product innovation and quality in Human Platelet Lysate and is in an excellent position to shape the market globally. I look forward to working with the highly qualified team to ensure PL BioScience’s commercial success.”